Cardiac Arrest after Patent Blue V Injection for Sentinel Lymph Node Biopsy in Breast Cancer

Bjorn Telgenkamp  Dennis Japink  Els van Haaren
Department of Surgery, Atrium Medical Centre, Heerlen, The Netherlands

Key Words
Sentinel node · Patent blue · Anaphylactic shock · Breast cancer

Summary
Background: Sentinel lymph node biopsy (SLNB) is a widely accepted method to determine lymph node status in for instance breast cancer, cervical cancer, or cutaneous melanomas. Although injection of blue dyes facilitates successful detection of sentinel nodes, they have also been shown to cause adverse reactions.

Case Report: A 62-year-old female patient was referred to the surgical department of the Atrium Medical Centre with a suspicious lesion located in the right breast, detected during population-based screening. Immediately after injection of patent blue V, the patient developed tachycardia on top of preexisting supraventricular tachycardia and showed an instant drop in blood pressure, after which cardiac arrest occurred. These clear symptoms of anaphylactic shock required prompt treatment, and the patient was treated accordingly.

Conclusions: Anaphylactic shock after injection of patent blue V remains a serious adverse event and warrants awareness. Immediate action with ephedrine, antihistamines, and subsequently corticosteroids can stabilize the patient. Tc-99m, isosulphan blue, and methylene blue can alternatively be used for SLNB, although also not without side effects.

Key Words
Sentinel-Lymphknoten · Patentblau · Anaphylaktischer Shock · Mammakarzinom

Zusammenfassung

Fallbericht: Eine 62-jährige Patientin war an die Chirurgische Abteilung des Atrium Medical Centre überwiesen worden, um eine suspekte Veränderung in der linken Brust, welche bei der Krebsvorsorgeuntersuchung entdeckt worden war, näher untersuchen zu lassen. Direkt nach Injektion des Patentblau V-Varbfarbstoffes entwickelte die Patientin Tachykardie zusätzlich zu einer vorbestehenden supraventrikulären Tachykardie und zeigte einen prompten Blutdruckabfall, nach welchem ein Herzstillstand eintrat. Diese eindeutigen Symptome eines anaphylaktischen Schocks erforderten ein promptes Eingreifen, und die Patientin wurde entsprechend behandelt.

Introduction

Sentinel lymph node biopsy (SLNB) is a widely accepted method to determine lymph node status in for instance breast cancer, cervical cancer, or cutaneous melanomas. Injection of a dye into a lymph vessel adjacent to the tumor site in addition to the use of Tc-99m enables detection of the sentinel node. Several dyes are currently available for this procedure. These include isosulphan blue, patent blue V, and methylene blue. Although injection of blue dyes has facilitated successful detection of sentinel nodes, they have also been shown to cause adverse reactions [1]. Besides local blue staining of the skin, complications vary from minimal tissue responses to mild and severe anaphylactic shock [2]. Especially the latter complication should be taken into account as it may result in death. The incidence of allergic reactions is 1–2.8% [2–8], but consequences can be severe and patent blue V is frequently applied. Therefore it remains imperative to maintain awareness regarding these severe complications. Here we report a severe case of anaphylactic shock after patent blue V injection for SLNB in a breast cancer patient.

Case Report

A 62-year-old female patient was referred to the surgical department of the Atrium Medical Centre with a suspicious lesion located in the right breast, detected during population-based screening. The medical history of the patient showed mitral valve prolapse grade II and paroxysmal supraventricular tachycardia. The patient’s medication comprised sotalol, digoxin, furosemide, acetylcysteine acid, and losartan. No pre-existing pulmonary disease, more specifically no asthma or chronic obstructive pulmonary disease, was diagnosed. Contact allergies, food allergies and signs of eczema had not occurred before, and she had never undergone surgery. To our knowledge, there was no prior sensitization to patent blue. Breast cancer was diagnosed by mammography and subsequent biopsy. Consequently, the patient was scheduled for a lumpectomy with a sentinel lymph node procedure. Preoperatively, alprazolam was administered. Anesthetic induction and maintenance was achieved with propofol, and sufentanil was used as analgesic. Fifteen minutes following induction of anesthesia, the surgical procedure was started with peri-auricular intracutaneous injection of 1 ml 2.5% patent blue V dye. Immediately after injection of the patent blue V, the patient developed tachycardia on top of her preexisting supraventricular tachycardia and showed an instant drop in blood pressure after which cardiac arrest occurred. These clear symptoms of anaphylactic shock required prompt treatment, and the patient was treated accordingly. Cardiac and fluid resuscitation were started immediately, and anti-anaphylactic therapy was provided with 0.5 mg intravenous (i.v.) bolus of ephedrine, 1 g i.v. hydrocortisone, and 20 mg i.v. tavegil. This resulted in improved cardiac output and successful conversion of the anaphylactic shock. After further stabilizing the patient, the SLNB was continued but the planned lumpectomy was postponed to first stabilize the patient and then plan a second operation depending on the outcome of the SLNB. Postoperatively, the patient was transferred to the intensive care unit for observation for 1 day. The SNLB showed no metastases in the sentinel nodes, and the patient was re-scheduled for a lumpectomy.

Discussion

At present, adequate treatment of breast cancer patients includes tumor mapping with SLNB. This enables detection of the lymph node that is most likely involved in the tumor process. Consequently, based on a histopathological analysis, a decision can be made whether complete dissection of the axillary lymph nodes is required. Sentinel lymph nodes are detected by injection of specific dyes. Currently, patent blue V, isosulphan blue, and methylene blue are available for this procedure. However, there are some reports of patients developing adverse reactions following injection. Symptoms are diverse and can include minor reactions such as urticaria, pruritus, erythema, generalized rash, and blue hives. Severe reactions such as pulmonary edema, bronchospasm, and shock are rare [5, 9]. To the best of our knowledge, no deaths have been reported. Allergic reactions have been graded from I to IV in order of increasing severity: grade I, cutaneous signs; grade II, measurable but not life-threatening signs (including cutaneous edema, > 30% decrease in arterial blood pressure associated with unexplained tachycardia, cough, or difficulty in mechanical ventilation); grade III, life-threatening reactions (cardiovascular collapse, tachycardia or bradycardia, arrhythmias, and severe bronchospasm); and grade IV, circulatory shock and cardiac arrest, respiratory arrest, or both. Based on several retrospective and prospective studies, the estimated incidence of reactions of all grades of severity varies from 1 to 2.8%, with severe (grade III and IV) reactions observed in 0.2–1.1% of cases [5, 10–12]. This case concerned a grade IV anaphylactic reaction by definition.

The incidence of anaphylactic shock after patent blue V is too low to discontinue this approach. Nevertheless, it remains imperative to keep reporting these severe cases in order to uphold vigilance. A sudden drop in blood pressure and increase in heart rate should direct the attention of the operating team towards an anaphylactic shock. Patients can be adequately stabilized with cardiac resuscitation, adrenergic support, mast cell stabilizing medication, and corticosteroids.

Mechanisms underlying allergic reactions to blue dyes have not been fully elucidated. Most likely, an IgE-mediated activation of mast cells causes this allergic response. IgE-based tests such as an enzyme-linked immunosorbent assay (ELISA) and skin Prick test support this view [9, 13]. An IgE-dependent response must of course be preceded by exposure to blue dyes. Since blue dyes are extensively used for commercial purposes such as cosmetics, textile, paper, medical products, sensitization is very well possible. In contrast, the Prick test does not provide an unequivocal true-positive

In conclusion, the use of blue-staining dyes for SLNB should be performed with adequate precautions in order to prevent severe adverse reactions. 

Acknowledgments

The authors would like to thank the patient for her consent and cooperation in the study.

Conflict of Interest

The authors have no conflict of interest to declare.

References

Methylene blue can be used as an alternative to patent blue V in addition to Tc-99m tin colloid use for patients with breast cancer undergoing SLNB [17].

In conclusion, anaphylactic shock after patent blue V injection remains a serious adverse event and warrants awareness. Immediate action with ephedrine, antihistamines, and subsequently corticosteroids can stabilize the patient. In high-risk patients, preventive anti-allergy medication should be applied before patent blue injection, or alternatively Tc-99m tin colloid, isosulphan blue, or methylene blue could be used for sentinel lymph node imaging.

Conflict of Interest

The authors declare no conflict of interest.

References